Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congressional "Best Price" Proposals Could Eradicate "Authorized" Generic Firms

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer generic subsidiary head Kennally says provision in pending legislation "will likely be overturned."

You may also be interested in...



FTC Accepts Senators’ Request To Study The Impact of Authorized Generics

The study is expected to take roughly two years to complete, the Federal Trade Commission said.

House Medicaid Reform Would Include Minimum Dispensing Fee For Generics

The Energy & Commerce Committee proposal lacks increases in rebates paid by manufacturers but includes increases in beneficiary cost-sharing.

Senate Finance Committee Proposes Including “Authorized” Generics In “Best Price”

Chairman Grassley’s budget reconciliation proposal, which will be voted on by the committee on Oct. 24, also increases minimum manufacturer rebates paid to the Medicaid program.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel